Nkarta to Participate in Evercore Healthcare Conference
Nkarta (Nasdaq: NKTX) will participate in the Evercore 8th Annual Healthcare Conference in Miami on December 4, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nkarta (Nasdaq: NKTX) will participate in the Evercore 8th Annual Healthcare Conference in Miami on December 4, 2025. Management will appear in a 10:50 a.m. ET fireside chat. A simultaneous webcast will be available on Nkarta’s Investors website, with a replay archived for approximately 90 days.
The presentation focuses on Nkarta’s clinical-stage engineered natural killer (NK) cell therapies for autoimmune diseases and provides an investor access point via live webcast and short-term replay.
Details
News Market Reaction – NKTX
On Dec 2, the day this news came out, NKTX closed 3.87% below the previous close.
Data tracked by StockTitan Argus for the Dec 2 session.
Key Figures
- Conference date
- December 4, 2025
- Evercore 8th Annual Healthcare Conference fireside chat
- Session time
- 10:50 a.m. ET
- Scheduled time for Evercore conference fireside chat
- Webcast replay period
- 90 days
- Replay of Evercore conference webcast available to investors
- Cash and investments
- $316.5M
- As of September 30, 2025 per Q3 2025 10-Q
- Net loss Q3 2025
- $21.7M
- Quarter ended September 30, 2025
- Operating expenses Q3 2025
- $27.3M
- Includes R&D $20.2M and G&A $7.1M
- Cash runway guidance
- Into 2029
- Management expectation from November 10, 2025 earnings release
- CMO stock options
- 500,000 shares at $1.75
- Options grant on June 23, 2025 per Form 4
Historical Context
-
Announcement of Evercore healthcare conference fireside chat and webcast access.
-
Q3 2025 results with strong cash balance and NKX019 autoimmune program progress.
-
Participation in November investor conferences with webcast and 90-day replay.
-
ACR poster showing robust CD19+ B-cell depletion and immune reset signals.
-
Announcement of H.C. Wainwright fireside chat with webcast and replay.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
natural killer (NK) cell therapies medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the Evercore 8th Annual Healthcare Conference on Thursday in Miami.
Evercore 8th Annual Healthcare Conference
December 4, 2025
10:50 a.m. ET – fireside chat
A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, and a replay will be archived on the website for approximately 90 days.
About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.
Nkarta Media/Investor Contact:
Nadir Mahmood
Nkarta, Inc.
nmahmood@nkartatx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.